MV140 is a sublingual bacterial vaccine developed by INMUNOTEK with effectiveness for the prevention of recurrent UTIs according to previous uncontrolled studies. The results presented by Dr. Mª Fernanda Lorenzo-Gómez (Complejo Asistencial Universitario de Salamanca, principal investigator of the study), entitled “MV140 Sublingual Vaccine Prevents Recurrent Urinary Tract Infections in Women” confirm the efficacy of this vaccine in a phase III, double-blind, placebo-controlled trial on 240 women, conducted in a multicenter manner between Spain and the United Kingdom.
July 2021. European Association of Urology (EAU21 Conference. 2021)Lorenzo-Gómez M, Foley, S, Nickel, JC, Padilla-Fernández, BY, Martínez-Huélamo, M, Yang, B, Saz-Leal, P, Casanovas, M, García-Cenador, MB. Efficacy and safety of the sublingual bacterial vaccine MV140 in women with recurrent urinary tract infections: a European phase III, multicentre, randomized, double-blind, placebo-controlled trial.